Lung Cancer Surgical Treatment Market Size, Share and Global Trend By Surgical Procedure (Pneumonectomy, Lobectomy, Segmentectomy, Sleeve Resection, Others), By End User (Hospitals, Clinics, Others) and Regional Forecast, 2024-2032

Lung cancer or lung carcinoma is a malignant tumor caused by uncontrolled cell growth in the tissues of the lungs. Lung cancer is categorized into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, Non-small cell lung cancer is sub-segmented into squamous cell carcinoma, large cell undifferentiated carcinoma, and adenocarcinoma.

Several stages of lung cancer are treated by chemotherapy or radiation therapy and the surgical treatment for lungs cancer is done in rare cases during the reoccurrence of lung cancer and failure of chemotherapy. Lung cancer surgery is ablation of lungs or cancer affected lobe. According to the American Cancer Society, about 228,150 new cases of lung cancer are estimated in the U.S. in 2019.

Increasing incidences of lung cancer due to change in lifestyle, smoking habits, genetic inheritance, and inhalation of carcinogenic substances are the factors driving the growth of the global lung cancer surgical treatment market. Lung cancer is the leading cause of cancer deaths worldwide is also responsible to drive the global lung cancer surgical treatment market owing to the rising demand for the prevention of cancer.

New surgical approaches like robotic surgery and other technological advancements such as minimally invasive surgical procedures are some of the factors expected to drive the growth of the global lung cancer surgical treatment market.

However, high treatment cost associated with surgeries and limited accessibility to new and advanced treatment techniques, especially in emerging countries are some the factors restraining the global lung cancer surgical treatment market.

Key Players Covered

Some of the key players present in the global lung cancer surgical treatment market are Covidien PLC, Ethicon US LLC, AngioDynamics Inc., Intuitive Surgical Inc., Accuray Inc., Teleflex Inc., Scanlan International Inc., Olympus Corporation, KARL STORZ GmbH, Ackermann Instrumente GmbH, Trokamed GmbH, and others.

SEGMENTATION

Among the segmentation, lobectomy in the surgical procedure segment accounts for larger market share and is anticipated to show a higher growth during the forecast period owing to its benefits, convenience, and effects even after the removal of the affected lobe from the lung.

Key Insights

• Technological advancements in lung cancer surgical treatment
• The regulatory scenario for key countries
• Reimbursement Scenario for key countries
• Key mergers and acquisitions

Regional Analysis

Geographically, the global lung cancer surgical treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a significant market share due to the higher prevalence of lung cancer, adequate reimbursement policies, and advanced healthcare infrastructure leading to increased adoption of technologically advanced techniques such as robotic surgery for the treatment of lung cancer. The Asia Pacific is expected to be lucrative market owing to rapid development in the healthcare sector, increase in the awareness regarding new developments in the lung cancer treatment among healthcare providers, and increasing adoption of technologically advanced techniques in Japan and emerging countries such as India and China.

Key Industry Developments

• In February 2019, Intuitive Surgical, Inc., announced U.S.FDA clearance for its ION ENDOLUMINAL system that enables minimal invasive biopsy in the peripheral lung.
• In November 2018, Auris Health, Inc., launched a monarch platform for advancements in robotics used in diagnosing and treating lung cancer. The integrated flexible robotic endoscope is responsible for endoscopic views.